OXFORD, UK – 14th January 2025 – Oxford Cancer Biomarkers Ltd (OCB), a leader in AI-driven, precision cancer diagnostics, has successfully met a major milestone with recruitment of the first patient into the clinical utility study of its precision oncology…
OXFORD, UK – 3rd April 2023 – Oxford Cancer Biomarkers Ltd (OCB), a leader in AI-driven, precision cancer diagnostics, has successfully closed its latest investment round. Plutus Investment Group LLP led the round, with participation from new and existing investors…
Oxford Cancer Biomarkers Ltd partners with York Health Economics Consortium to demonstrate OncoProg ® cost-effectiveness within the health service OXFORD, UK – July 29th, 2021 – Oxford Cancer Biomarkers Ltd (OCB), a pioneer in precision…
Oxford Cancer Biomarkers achieves CE mark for OncoProg ® digital pathology computational software product OXFORD, UK – July 19th, 2021 – Oxford Cancer Biomarkers (OCB), a pioneer in precision medicine, today announced it has received a CE mark for OncoProg…
Oxford Cancer Biomarkers are pleased to announce the rebranding of our ColoProg ® product to OncoProg ® OXFORD, UK – April 21st, 2021 – OncoProg ® is a cutting-edge digital pathology prognosis tool that provides a more complete understanding of…
Today, Oxford Cancer Biomarkers are pleased to announce the publication of the ToxNav ® clinical validation study in the journal Cancers. This milestone represents a significant step forward for OCB and the ToxNav ® brand. ToxNav ® is OCB’s flag…
The team at Oxford Cancer Biomarkers (OCB) are pleased to announce the expansion of our ToxNav® DPYD genomics panel with the inclusion of HAPB3. Effective from the 6th October 2020, the ToxNav® panel will contain one additional genetic variant (HAPB3;…
Today I am incredibly proud to be supporting the launch of the 5FU Test Alliance support group. They comprise a small band of brave people who have either lost a loved one or suffered toxic events themselves, as a result…
Today 25 September 2019, OCB are presenting with IBM at Pharmatec19 – London Room 7 at 11:20 – Using AI Technology To Improve Outcomes For Cancer Patients. OCB aim to benefit cancer patients by implementing advanced precision oncology diagnostics. James Otter,…
We are grateful to Rebecca for writing this and for her participation in the continuous improvement in our ToxNav® panel. She is an inspirational young woman and we salute her tenacity, please read and share to encourage others to seek…